Table 1 DHMEQ-mediated sensitizing effect to anticancer agents in T24 and T24PR cells
anticancer agents | T24 | T24PR | combination with DHMEQ (3 μg/ml) in T24PR | ||
|---|---|---|---|---|---|
IC50 ± SE | IC50 ± SE | RF | IC50 ± SE | CI | |
cisplatin(μM) | 4.5 ± 0.1 | 27 ± 1.5 | 5.9 | 9.8 ± 0.6 | 0.75 |
gemcitabine(nM) | 231 ± 25 | 910 ± 33 | 3.9 | 124 ± 5.1 | 0.71 |
paclitaxel(nM) | 49 ± 1.8 | 62 ± 2.6 | 1.3 | 20 ± 1.1 | 0.79 |
carboplatin(μM) | 65 ± 2.8 | 208 ± 9.8 | 3.2 | 75 ± 5.5 | 0.74 |